Watson Pharmaceuticals has completed its 4.25 billion Euro acquisition of Swiss competitor Actavis Group, making Watson the third-largest generic drug company worldwide. BDK advised Watson on their acquisition of Actavis’ Serbian subsidiary. BDK’s team was led by partner Vladimir Dasic.
Bulevar knjaza Danila Petrovića 11, The Capital Plaza
81000 Podgorica, Montenegro
T/F: +382 20 230 396
(Attorneys Dijana Pejić and Nikolina Bajić in cooperation with BDK Advokati AOD)
Bulevar srpske vojske 17
78000 Banja Luka
T: +387 51 250 640, +387 51 250 641
F: +387 51 250 642
Strictly necessary cookies are essential for the proper functioning of our website, for example by ensuring that the visual elements on a webpage are displayed in the proper format and layout. See Cookie Policy for more information.
